The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Non-Viral Drug Delivery Systems (Focus on Intracellular Technologies and Intracellular Biologics) Market by Type of Molecule (RNAi / mRNA, DNA oligonucleotides, antibodies, proteins / peptides and small molecules) and Key Geographies (North America, Europe, Asia Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2021-2030 [Upcoming Report]

  • Lowest Price Guaranteed From USD 5,499

  • Published
    February 2021

  • Pages
    256

  • View Count
    1031

Example Insights

Non-Viral-Drug-Delivery-Systems-Market-Context Non-Viral-Drug-Delivery-Systems-Market-List-Of-Developers Non-Viral-Drug-Delivery-Systems-Market-Different-types-of-vehicles
Non-Viral-Drug-Delivery-Systems-Market-Patent-Analysis Non-Viral-Drug-Delivery-Systems-Market-Competitiveness-Analysis Non-Viral-Drug-Delivery-Systems-Market-Partnerships-and-Collaborations
Non-Viral-Drug-Delivery-Systems-Market-Opportunity    

 

Overview

Over time, advances in molecular biology and pharmacological chemistry have enabled the identification of biological targets localized in the subcellular space, and development of therapeutic leads against them. In fact, there are several clinical conditions, which were previously considered undruggable since the traditional small molecule-based interventions were unable to penetrate the selectively permeable cell membrane. Presently, there are many biopharmaceuticals interventions that are designed to bind to intracellular proteinaceous entities responsible for causing a number of diseases. Given the limited targeting capabilities of small molecule drugs (experts estimate that such therapeutics can selectively bind to only 10% of the human genome), biologics, especially nucleic acid-based therapies represent the future of pharmacology. Interestingly, most biotherapeutics need to penetrate the cell membrane in order to mediate their therapeutic effects. Considering the fact that over 20% of the proteome, which includes a large number of viable therapeutic targets, is localized within the cell membrane, the need to facilitate the intracellular delivery of several novel drugs / therapies is considered to be one of the major challenges within the modern pharmaceutical industry.

Over time, medical researchers have developed a variety of virus-based and non-viral strategies to facilitate the entry of pharmacological molecules into the cytosol. Examples include cell penetrating peptides (CPP), DNA-dependent technologies, exosome-based drug delivery systems and nanoparticles based mechanisms. Recently, there was a surge in the demand for intracellular drug delivery solutions for multiple mRNA therapeutics and preventive interventions being developed against COVID-19. In fact, the vaccines developed by Moderna and Pfizer / BioNTech use lipid nanoparticles to facilitate the intracellular delivery of their respective mRNA payloads. In the recent past, various technology developers have forged strategic alliances with therapy developers to support the development of drug formulations that can be targeted to the intracellular space. Given the growing demand for interventions that require cell internalization, the intracellular drug delivery technologies market is poised to witness substantial growth in the foreseen future.

Scope of the Report

The “Non-Viral Drug Delivery Systems: Focus on Intracellular Technologies and Intracellular Biologics Market, 2021-2030” report features an extensive study of the current landscape and the likely future opportunities in intracellular drug delivery technologies market for the next 10 years. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the intracellular drug delivery technologies, featuring an in-depth analysis based on a number of parameters, such as type of molecule delivered, type of biologic delivered, type of bond between the vehicle and the payload, type of vehicle used, and availability of intellectual property. In addition, the chapter features a list of technology developers and a detailed analysis based on year of establishment, company size and geographical location.
  • A detailed competitiveness analysis of intracellular drug delivery technologies, taking into consideration the supplier power (based on the year of establishment of the developer) and key technology specifications, such as availability of intellectual property, number of deals signed during 2015 - 2020, number of products / programs developed based on technologies and type of molecule(s) delivered (biologics / small molecules). 
  • An in-depth analysis of the patents filed for intracellular drug delivery technologies based on various relevant parameters, such as publication year, geographical location, issuing authority, assigned CPC symbol, highlighting the emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to technology platforms), product development and commercialization agreements, manufacturing agreements, mergers and acquisitions, and other relevant agreements.
  • Elaborate profiles of prominent technology developers engaged in this domain. Each profile features a brief overview of the company, its financial information (if available), information on its technology portfolio, recent developments and an informed future outlook.
  • A case study on the molecules developed / being developed using the intracellular drug delivery technology with analysis based on the phase of development, type of molecule and the target disease indication.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for intracellular drug delivery technologies. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2021-2030. The report features likely distribution of the current and forecasted opportunity across the [A] type of molecule delivered (DNA, RNA, small molecule and others), and [B] key geographical regions (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Tehila Ben-Moshe, and Itay Friedman (Chief Executive Officer and Chief Scientific Officer, Biond Biologics)
  • Anders Høgset (Chief Scientific Officer, PCI Biotech)
  • Melissa Wagner (Senior Director, Business Development, SRI International)

Key Questions Answered

  • Who are the leading players engaged in development of intracellular drug delivery technologies?
  • Which partnership models are commonly adopted by stakeholders engaged in this domain?
  • What type of molecule can be delivered using intracellular drug delivery technologies?
  • How is the intellectual property landscape likely to evolve in the foreseen future?
  • How is the current and future market opportunity likely to be distributed across key market segments and geographical region?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the intracellular drug delivery technologies market and describes its evolution in the short-mid-term and long term.

Chapter 3 provides an introduction to the concept of intracellular drug delivery technologies. It highlights the need for targeted drug delivery and approaches used for intracellular drug delivery. In addition, it discusses the future perspectives of this segment of the pharmaceutical industry.

Chapter 4 provides an overview of the overall market landscape of intracellular drug delivery technologies, featuring a comprehensive list of technologies and analysis based on a number of parameters, such as type of molecule delivered, type of biologic delivered, type of bond between the vehicle and the payload, type of vehicle used, and information on intellectual property. It also includes a list of technology developers and a detailed analysis based on year of establishment, company size and geographical location. 

Chapter 5 presents a detailed competitiveness analysis of intracellular drug delivery technologies, based on the supplier power (based on the year of establishment of developer company) and key technology specifications, such as (in alphabetical order) availability of intellectual property, number of deals signed during 2015-2020, number of products / programs developed based on technologies and type of molecule(s) delivered (biologics / small molecules). 

Chapter 6 features detailed profiles of prominent technology developers in this domain. Each profile includes a brief overview of the company, its financial performance (if available), information on its technology portfolio, recent developments and a comprehensive future outlook.

Chapter 7 provides an in-depth analysis of patents filed for intracellular drug delivery technologies based on the parameters, such as publication year, geographical location, issuing authority and assigned CPC symbol, highlighting the emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 8 features an elaborate discussion of the various collaborations and partnerships that have been established in the recent past. It includes a brief description of various types of partnership models, such as R&D collaborations, licensing agreements (specific to technology platforms), product development and commercialization agreements, manufacturing agreements, and mergers and acquisitions. In addition, it includes a detailed analysis of partnerships, based on year of partnership, type of partnership, and regional activity.

Chapter 9 is a case study providing detailed insights on current market landscape of intracellular therapies developed using intracellular drug delivery technologies. In addition, it includes a detailed analysis of these therapies based on parameters, such as type of molecule, phase of development, target disease indication, therapeutic areas, route of administration and delivery technology used.

Chapter 10 presents an insightful market forecast analysis, highlighting likely growth of intracellular drug delivery technologies market till the year 2030, on the basis of likely licensing deal structures and agreements that are expected to be signed in the foreseen future. We have provided inputs on the likely distribution of the opportunity by type molecule (DNA, RNA, small molecules and others), and key geographical regions (North America, Europe, Asia Pacific and rest of the world).
 
Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the drug delivery technology industry.

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Anders Høgset (Chief Scientific Officer, PCI Biotech), Melissa Wagner (Senior Director, Business Development, SRI International), Tehila Ben-Moshe, and Itay Friedman (Chief Executive Officer and Chief Scientific Officer, Biond Biologics).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Challenges Associated with Intracellular Delivery of Biologics
3.3. Need for Targeted Drug Delivery
3.4. Intracellular Drug Delivery Approaches 
3.4.1. Muco-Adhesive Polymeric Systems 
3.4.2. Nanoparticle-based Delivery Systems
3.4.3. Other Drug Delivery Technologies
3.5. Future of Intracellular Drug Delivery

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Intracellular Drug Delivery Technologies: List of Technologies
4.2.1. Analysis by Type of Molecule Delivered 
4.2.2. Analysis by Type of Biologic Delivered
4.2.3. Analysis by Type of Linkage
4.2.4. Analysis by Type of Vehicle Used
4.2.5. Analysis by Availability of Intellectual Property

4.3. Intracellular Drug Delivery Technologies: List of Technology Developers
4.3.1 Analysis by Year of Establishment
4.3.2 Analysis by Company Size
4.3.3 Analysis by Location of Headquarters

4.4. Intracellular Drug Delivery: List of Other Technologies

5. TECHNOLOGY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.4. Technology Competitiveness Analysis: Intracellular Drug Delivery Technologies
5.4.1. Technologies Developed by Companies based in North America
5.4.2. Technologies Developed by Companies based in Europe
5.4.3. Technologies Developed by Companies based in Asia-Pacific / Rest of the World
 
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Arcturus Therapeutics
6.2.1. Company Overview
6.2.2. Technology Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Bio-Path Holdings
6.3.1. Company Overview
6.3.2. Technology Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. CureVac
6.4.1. Company Overview
6.4.2. Technology Portfolio
6.4.3. Recent Developments and Future Outlook

6.5. Entos Pharmaceuticals
6.5.1. Company Overview
6.5.2. Technology Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. eTheRNA immunotherapies
6.6.1. Company Overview
6.6.2. Technology Portfolio
6.6.3. Recent Developments and Future Outlook

6.7. PCI Biotech
6.7.1. Company Overview
6.7.2. Technology Portfolio
6.7.3. Recent Developments and Future Outlook

7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Intracellular Drug Delivery Technologies: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Issuing Authority / Patent Offices Involved
7.3.3. Analysis by CPC Symbols
7.3.4. Word Cloud: Emerging Focus Areas
7.3.5. Analysis by Type of Organization
7.3.6. Leading Players: Analysis by Number of Patents
 
7.4. Intracellular Drug Delivery Technologies: Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.4.2. Analysis by Patent Valuation

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Intracellular Drug Delivery Technologies: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Therapeutic Area
8.3.4. Analysis by Year of Partnership and Type of Partner
8.3.5. Analysis by Type of Partnership and Type of Partner
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Most Popular Technologies: Analysis by Number of Partnerships
8.3.8. Regional Analysis
8.3.9. Intercontinental and Intracontinental Agreements

9. CASE STUDY: INTRACELLULAR THERAPIES
9.1. Chapter Overview
9.2. Intracellular Therapies: Pipeline Review
9.2.1. Analysis by Type of Molecule 
9.2.2. Analysis by Phase of Development
9.2.3. Analysis by Target Indications
9.2.4. Analysis by Therapeutic Areas
9.2.5. Analysis by Route of Administration
9.2.6. Analysis by Delivery Technology Used

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions
10.3. Forecast Methodology
10.4. Global Intracellular Drug Delivery Technologies Market, 2021-2030
10.5. Intracellular Drug Delivery Technologies Market: Distribution by Type of Molecule, 2021-2030
10.5.1. Intracellular Drug Delivery Technologies Market for RNA Molecules, 2021-2030
10.5.2. Intracellular Drug Delivery Technologies Market for DNA Molecules, 2021-2030
10.5.3. Intracellular Drug Delivery Technologies Market for Small Molecules, 2021-2030
10.5.4. Intracellular Drug Delivery Technologies Market for Other Molecules, 2021-2030

10.6. Intracellular Drug Delivery Technologies Market: Distribution by Region, 2021-2030
10.6.1. Intracellular Drug Delivery Technologies Market in North America, 2021-2030
10.6.2. Intracellular Drug Delivery Technologies Market in Europe, 2021-2030
10.6.3. Intracellular Drug Delivery Technologies Market in Asia-Pacific / Rest of the World, 2021-2030

11. CONCLUDING REMARKS
11.1. Chapter Overview
11.2. Key Takeaways

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Biond Biologics
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Tehila Ben-Moshe and Itay Friedman, (Chief Executive
 Officer and Chief Scientific Officer)

12.3. PCI Biotech
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Anders Høgset (Chief Scientific Officer)

12.4. SRI International
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Melissa Wagner (Senior Director, Business Development)

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Types of Biological Products
Figure 3.2 Comparison of Key Characteristics of Biologics and Small Molecules
Figure 3.3 Mechanism of Drug Transport through Intestinal Epithelium
Figure 4.1 Intracellular Drug Delivery Technologies: Distribution by Type of Molecule Delivered
Figure 4.2 Intracellular Drug Delivery Technologies: Distribution by Type of Biologic Delivered
Figure 4.3 Intracellular Drug Delivery Technologies: Distribution by Type of Linkage
Figure 4.4 Intracellular Drug Delivery Technologies: Distribution by Type of Vehicle Used
Figure 4.5 Intracellular Drug Delivery Technologies: Distribution by Availability of Intellectual Property
Figure 4.6 Intracellular Drug Delivery Technology Providers: Distribution by Year of Establishment
Figure 4.7 Intracellular Drug Delivery Technology Providers: Distribution by Company Size
Figure 4.8 Intracellular Drug Delivery Technology Providers: Distribution by Location of Headquarters
Figure 4.9 World Map Representation: Analysis by Location of Headquarters
Figure 5.1 Competitiveness Analysis: Technologies Developed by Companies based in North America
Figure 5.2 Competitiveness Analysis: Technologies Developed by Companies based in Europe
Figure 5.3 Competitiveness Analysis: Technologies Developed by Companies based in Asia-Pacific / Rest of the World
Figure 7.1 Patent Analysis: Distribution by Type of Patent
Figure 7.2 Patent Analysis: Cumulative Distribution by Publication Year
Figure 7.3 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Figure 7.4 Patent Analysis: Distribution by CPC Symbols
Figure 7.5 Word Cloud: Emerging Focus Areas
Figure 7.6 Patent Analysis: Cumulative Distribution by Type of Organization
Figure 7.7 Leading Industry Players: Distribution by Number of Patents
Figure 7.8 Leading Non-Industry Players: Distribution by Number of Patents
Figure 7.9 Leading Individual Assignees: Distribution by Number of Patents
Figure 7.10 Patent Analysis (Leading Industry Players): Benchmarking by Patent Characteristics (CPC Classifications)
Figure 7.11 Patent Analysis: Distribution of Patents by Age (2001-2020)
Figure 7.12 Intracellular Drug Delivery Technologies: Patent Valuation
Figure 8.1 Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2015-2020
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2020)
Figure 8.4 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.5 Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
Figure 8.6 Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Figure 8.7 Partnerships and Collaborations: Most Active Players
Figure 8.8 Partnerships and Collaborations: Most Popular Technologies
Figure 8.9 Partnerships and Collaborations: Regional Distribution
Figure 8.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Intracellular Therapeutics: Distribution by Type of Molecule
Figure 9.2 Intracellular Therapeutics: Distribution by Phase of Development
Figure 9.3 Intracellular Therapeutics: Distribution by Target Indications
Figure 9.4 Intracellular Therapeutics: Distribution by Therapeutic Areas
Figure 9.5 Intracellular Therapeutics: Distribution by Route of Administration
Figure 9.6 Intracellular Therapies: Distribution by Delivery Technology Used
Figure 10.1 Licensing Agreements: Distribution of Financial Component
Figure 10.2 Technology Licensing Deal: Payment Structure
Figure 10.3 Intracellular Drug Delivery Technologies Market, 2021-2030 (USD Million)
Figure 10.4 Global Intracellular Drug Delivery Technologies Market: Distribution by Type of Molecule, 2021 and 2030 (USD Million)
Figure 10.5 Intracellular Drug Delivery Technologies Market for RNA Molecules, 2021-2030 (USD Million)
Figure 10.6 Intracellular Drug Delivery Technologies Market for DNA Molecules, 2021-2030 (USD Million)
Figure 10.7 Intracellular Drug Delivery Technologies Market for Small Molecules, 2021-2030 (USD Million)
Figure 10.8 Intracellular Drug Delivery Technologies Market for Other Molecules, 2021-2030 (USD Million)
Figure 10.9 Global Intracellular Drug Delivery Technologies Market: Distribution by Region, 2021 and 2030 (USD Million)
Figure 10.10 Intracellular Drug Delivery Technologies Market in North America, 2021-2030 (USD Million)
Figure 10.11 Intracellular Drug Delivery Technologies Market in Europe, 2021-2030 (USD Million)
Figure 10.12 Intracellular Drug Delivery Technologies Market in Asia-Pacific / Rest of the World, 2021-2030 (USD Million)

List Of Tables

Table 4.1 List of Intracellular Drug Delivery Technologies
Table 4.2 Intracellular Drug Delivery Technologies: Information on Type of Biologic Delivered
Table 4.3 List of Intracellular Drug Delivery Technology Developers
Table 4.4 List of Other Technologies
Table 6.1 List of Companies Profiled
Table 6.2 Arcturus Therapeutics: Company Snapshot
Table 6.3 Technology Profile: LUNAR®
Table 6.4 Arcturus Therapeutics: Recent Developments and Future Outlook
Table 6.5 Bio-Path Holdings: Company Snapshot
Table 6.6 Technology Profile: DNAbilize®
Table 6.7 Bio-Path Holdings: Recent Developments and Future Outlook
Table 6.8 CureVac: Company Snapshot
Table 6.9 Technology Profile: mRNA technology
Table 6.10 CureVac: Recent Developments and Future Outlook
Table 6.11 Entos Pharmaceuticals: Company Snapshot
Table 6.12 Technology Profile: Fusogenix
Table 6.13 Entos Pharmaceuticals: Recent Developments and Future Outlook
Table 6.14 eTheRNA immunotherapies: Company Snapshot
Table 6.15 Technology Profile: TriMix technology
Table 6.16 eTheRNA immunotherapies: Recent Developments and Future Outlook
Table 6.17 PCI Biotech: Company Snapshot
Table 6.18 Technology Profile: Photochemical internalisation
Table 6.19 PCI Biotech: Recent Developments and Future Outlook
Table 7.1 Patent Analysis: CPC Symbol Definitions
Table 7.2 Patent Analysis: Most Popular CPC Symbols
Table 7.3 Patent Analysis: List of Top CPC Symbols
Table 7.4 Patent Analysis: Summary of Benchmarking Analysis
Table 7.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 7.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 7.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 8.1 Intracellular Drug Delivery Technologies: Partnerships and Collaborations, 2015-2020
Table 9.1 Intracellular Therapeutics: List of Drugs
Table 10.1 Technology Licensing Deals: Tranches of Milestone Payments
Table 10.2 Intracellular Drug Delivery Technologies: Average Upfront Payments and Average Milestone Payments (USD Million)

List Of Companies

The following companies and organizations are mentioned in the report.

  1. 20Med Therapeutics
  2. Abcam 
  3. Acuitas Therapeutics
  4. Alcobra
  5. Alexion Pharmaceuticals
  6. Alligator Bioscience
  7. Alnylam Pharmaceuticals
  8. AM Chemicals 
  9. Amgen
  10. Aquarius Biotechnologies
  11. Arbutus Biopharma
  12. Arcturus Therapeutics
  13. Arrowhead Pharmaceuticals
  14. Aruna Bio
  15. AskBio
  16. Astellas Innovation Management 
  17. AstraZeneca
  18. Avicenna Oncology
  19. Avidity Biosciences
  20. Axolabs
  21. Bavarian Nordic
  22. Bayer
  23. BioCellChallenge
  24. BioInvent International
  25. BioMoti
  26. Biond Biologics
  27. Bioneer
  28. BioNTech
  29. BioPact Ventures
  30. Bio-Path Holdings
  31. Blueberry Therapeutics
  32. Boehringer Ingelheim
  33. Casebia Therapeutics
  34. Catalent 
  35. Cellectar Biosciences
  36. Centre for Probe Development and Commercialization
  37. Chimeron Bio
  38. China Medical System
  39. Codiak BioSciences
  40. Complix
  41. CRISPR Therapeutics
  42. Cristal Therapeutics
  43. CureVac
  44. Curida
  45. Cybrexa Therapeutics
  46. Cytiva
  47. Daiichi Sankyo
  48. DCPrime
  49. Dicerna Pharmaceuticals
  50. Duke-NUS Medical School
  51. Eli Lilly
  52. Emisphere Technologies
  53. EnGeneIC
  54. Entos Pharmaceuticals
  55. Entrada Therapeutics
  56. EpiVax
  57. eTheRNA immunotherapies
  58. ethris
  59. Evox Therapeutics
  60. Feldan Therapeutics
  61. Frame Therapeutics
  62. Genenech 
  63. Genevant Sciences
  64. Genmab 
  65. GlaxoSmithKline
  66. Green Cross LabCell 
  67. Gritstone Oncology 
  68. Gustave Roussy
  69. Helmholtz Zentrum München
  70. Hopewell Therapeutics
  71. ILIAS Biologics
  72. Image Analysis Group (IAG)
  73. IMV Technologies
  74. INC Research
  75. In-Cell-Art
  76. Intezyne Technologies
  77. Ionis Pharmaceuticals
  78. Iovance Biotherapeutics
  79. IXALTIS
  80. Janssen Pharmaceuticals
  81. Jazz Pharmaceuticals
  82. Keystone Nano
  83. Larimar Therapeutics
  84. Leland Stanford Junior University 
  85. LGC
  86. LiberaBio
  87. Lions Eye Institute
  88. Mallinckrodt Pharmaceuticals
  89. Massachusetts Institute of Technology
  90. Matinas BioPharma
  91. Medigene
  92. Merck
  93. Merrimack Pharmaceuticals
  94. MirImmune
  95. University of Münster
  96. Mymetics
  97. N4 Pharma
  98. National Center for Cancer Immune Therapy (CCIT-DK)
  99. National Institutes of Health
  100. Nature Technology
  101. Neurimmune
  102. Nitto Denko
  103. Novartis
  104. Novo Nordisk
  105. Nutcracker Therapeutics
  106. Oisin Biotechnologies
  107. OliX Pharmaceuticals
  108. Onconova Therapeutics
  109. OnCore Biopharma
  110. Orum Therapeutics
  111. Pantherna Therapeutics
  112. PCI Biotech
  113. Pfizer
  114. PhaseRx
  115. Phio Pharmaceuticals
  116. pHion Therapeutics
  117. Precision NanoSystems
  118. PROVIREX Genome Editing Therapies
  119. PYC Therapeutics
  120. Regulus Therapeutics
  121. ReNeuron
  122. Rexahn Pharmaceuticals
  123. Rhode Island Council on Postsecondary Education
  124. RiboBio
  125. Roche
  126. Roivant Sciences
  127. Sanofi Pasteur
  128. Sapreme Technologies
  129. Sarepta Therapeutics
  130. Schepens Eye Research Institute
  131. Selexis
  132. Shire 
  133. Silence Therapeutics
  134. Sirnaomics
  135. SomaServe
  136. SQZ Biotech
  137. SRI International
  138. Stemirna Therapeutics
  139. Synthetic Genomics
  140. Takeda Pharmaceuticals 
  141. Théa Open Innovation
  142. Translate Bio
  143. Ultimovacs
  144. Ultragenyx Pharmaceutical
  145. Université Libre De Bruxelles
  146. University of California
  147. University of Michigan
  148. University of Oxford
  149. University of Pennsylvania
  150. University of Texas
  151. University of Washington
  152. Vesigen Therapeutics
  153. ViiV Healthcare
  154. Vlaams Instituut voor Biotechnologie
  155. Vrije Universiteit Brussel
  156. Wayne State University
  157. Wisconsin Alumni Research Foundation
  158. Xigen
  159. Yale University
  160. Zhejiang Haichang Biotechnology

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com